Press Releases

July 28, 2005

Gilead Sciences Announces Management Promotions

FOSTER CITY, Calif., Jul 28, 2005 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of Gregg Alton to Senior Vice President and General Counsel and the promotion of Taiyin Yang, PhD, to Senior Vice President, Pharmaceutical Development and Manufacturing.

Mr. Alton joined Gilead in 1999 and was promoted to Vice President in 2001. He was named to Gilead's Executive Committee in 2004. As Senior Vice President and General Counsel, he is responsible for legal affairs as well as Gilead's government affairs activities, reporting to John C. Martin, PhD, Gilead's President and Chief Executive Officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward LLP, where his practice focus was mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. He is Chairman of the Board of BayBio, a San Francisco Bay Area life sciences industry organization, a member of the board of the AIDS Healthcare Foundation, member of the board and treasurer of the Biotechnology Industry Organization's General Counsel Committee, and a member of the advisory board of BIO Ventures for Global Health. Mr. Alton received his JD from Stanford Law School and his bachelor's degree from the University of California at Berkeley.

"Gregg's leadership and his contributions across the Gilead organization make him an invaluable member of our team," said Dr. Martin. "His knowledge and depth of understanding of the functional areas of operation within Gilead allow him to play a pivotal role in advancing initiatives that further our corporate goals and mission."

Dr. Yang joined Gilead in 1993, and was promoted to Vice President in 1999. In her role as Senior Vice President, Pharmaceutical Development and Manufacturing, Dr. Yang is responsible for managing the formulation and production of active pharmaceutical ingredients for Gilead's commercial and investigational products. Dr. Yang reports to Norbert Bischofberger, PhD, Gilead's Executive Vice President of Research and Development, and with this promotion joins Gilead's Executive Committee. Prior to joining Gilead, Dr. Yang was Director of Analytical Chemistry at Syntex. She is a member of the American Association of Pharmaceutical Scientists, a member of the American Chemical Society, and a member of the Drug Information Association. Dr. Yang received her bachelor's degree in Chemistry from National Taiwan University and her PhD in Organic Chemistry from the University of Southern California.

"Taiyin has 25 years of experience in the biopharmaceutical industry, and it is this expertise that has facilitated the successful work to formulate and manufacture the compounds in our expanding portfolio of products," said Dr. Bischofberger. "In particular, with the growth of Gilead and our marketed products, Taiyin and her team have effectively managed the rapid scale-up of production of active pharmaceutical ingredients for our antiretrovirals for HIV."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Erin Edgley, 650-522-5635 (Media)